Disrupting the MYCN enhancer regulatory axis and targeting SEs holds promise as therapeutic strategies in NB, offering potential avenues to inhibit oncogenic transcription and inhibit tumor growth [154,155]. This evidence concerns the gene MYCN and neuroblastoma.